13 completed. 13 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 13 |
| Phase 2 | 1 | Completed 1 |
Follow Multiple System Atrophy: new trials by email Literature Review of Multiple System Atrophy trials Research Report on Multiple System Atrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| UB-312 in Patients With Synucleinopathies UB-312 Injection, Placebo Injection - Multiple System Atrophy, Parkinson Disease | Phase 1 | Completed | NYU Langone Health | 8 | 2023-05-31 | 2026-03-16 |
| Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID stellate ganglion block with 0.5% bupivacaine - Post Acute COVID-19 Syndrome, Long COVID | Phase 1 | Completed | Jonathann Kuo, MD | 20 | 2023-01-03 | 2025-03-13 |
| A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b) anle138b (TEV-56286), Fluvoxamine 100 mg QD for 5 days - Healthy Volunteers | Phase 1 | Completed | MODAG GmbH | 54 | 2022-09-12 | 2023-03-23 |
| Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein [18F]UCB-2897 - Parkinson Disease, Multisystem Atrophy | Phase 1 | Completed | Invicro | 5 | 2022-01-31 | 2025-02-20 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease anle138b, Placebo - Parkinson Disease | Phase 1 | Completed | MODAG GmbH | 70 | 2020-12-22 | 2023-03-22 |
| A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy Subjects anle138b, Placebo - Healthy Volunteers | Phase 1 | Completed | MODAG GmbH | 68 | 2019-12-06 | 2020-08-06 |
| Safety and Tolerability of CS10BR05 Inj. in Subjects with Multiple System Atrophy CS10BR05 - Multiple System Atrophy | Phase 1 | Completed | Corestemchemon, Inc. | 9 | 2018-04-13 | 2024-10-18 |
| Automated Abdominal Binder for Orthostatic Hypotension automated abdominal binder, Sham binder, Placebo - Orthostatic Hypotension, Autonomic Failure | Phase 1 / Phase 2 | Completed | Vanderbilt University Medical Center | 28 | 2018-03-01 | 2026-05-05 |
| Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure Abdominal compression, Sham abdominal compression, Placebo pill - Orthostatic Hypotension, Pure Autonomic Failure | Phase 1 | Completed | Vanderbilt University Medical Center | 21 | 2015-04-01 | 2026-05-05 |
| Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA AFFITOPE® PD01A + Adjuvant, AFFITOPE® PD03A + Adjuvant, Adjuvant without active component - Multiple System Atrophy, Neurodegenerative Diseases | Phase 1 | Completed | Affiris AG | 30 | 2014-12-11 | 2017-06-05 |
| Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy Fludrocortisone, Domperidone, Conservative Measures for Orthostatic Hypotension - Parkinson's Disease, Multiple System Atrophy | Phase 1 | Completed | Royal Brisbane and Women's Hospital | 50 | 2005-01-01 | 2005-10-20 |
| The Autonomic Nervous System and Obesity Trimethaphan, Pseudoephedrine - OBESITY, HYPERTENSION | Phase 1 | Completed | Vanderbilt University | 128 | 2003-04-01 | 2018-03-01 |
| Treatment of Supine Hypertension in Autonomic Failure Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox) - Hypertension | Phase 1 | Completed | Vanderbilt University | 152 | 2001-01-01 | 2017-10-13 |
Parkinson Disease (6) · Neurodegenerative Diseases (4) · Pure Autonomic Failure (4) · Alzheimer Disease (3) · Hypotension, Orthostatic (3) · Parkinson Disease 4, Autosomal Dominant Lewy Body (3) · Shy-Drager Syndrome (3) · Tauopathies (3) · Hypertension (2) · Autonomic Nervous System Diseases (1) · COVID-19 (1) · Dysautonomia like disorder (1) · Obesity (1) · Post-Acute COVID-19 Syndrome (1)
Basal Ganglia Diseases (13) · Brain Diseases (13) · Central Nervous System Diseases (13) · Movement Disorders (13) · Nervous System Diseases (13) · Primary Dysautonomias (13) · Autonomic Nervous System Diseases (12) · Synucleinopathies (11) · Neurodegenerative Diseases (7) · Cardiovascular Diseases (6) · Hypotension (6) · Parkinsonian Disorders (6) · Vascular Diseases (6) · Dementia (3) · Mental Disorders (3)
3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole (3) · Midodrine (2) · Adjuvants, Pharmaceutic (1) · Arginine (1) · Aspirin (1) · Aspirin, Dipyridamole Drug Combination (1) · Bosentan (1) · Bupivacaine (1) · Caffeine (1) · Captopril (1) · Carbidopa (1) · Clonidine (1) · Deamino Arginine Vasopressin (1) · Diltiazem (1) · Dipyridamole (1)
MODAG GmbH (3) · Vanderbilt University (2) · Vanderbilt University Medical Center (2) · Affiris AG (1) · Corestemchemon, Inc. (1) · Invicro (1) · Jonathann Kuo, MD (1) · NYU Langone Health (1) · Royal Brisbane and Women's Hospital (1)
United States (7) · United Kingdom (3) · Australia (1) · France (1) · South Korea (1)
Italo Biaggioni, MD (4) · Luis E Okamoto, MD (2) · Nand Singh, BSc, MD, DPM, MFPM (2) · Amy Knorr, MD (1) · David Russell, MD, Ph.D (1) · Horacio Kaufmann, MD (1) · Jonathan Evans, MD (1) · Jonathann Kuo, MD (1) · Joyce Gibbons, PA-C (1) · Kerrie Schoffer, MBBS (1) · Nand Singh, MD (1) · Phil Hyu Lee, M.D. (1) · Wassilios Meissner, MD, PhD (1)
PMID 10851208, PMID 11927799, PMID 12119802, PMID 12923400, PMID 15738343, PMID 16391172, PMID 16533484, PMID 17116758, PMID 18426998, PMID 19047577, PMID 19738158, PMID 22469621, PMID 22801444, PMID 23266540, PMID 32882100, PMID 34000076, PMID 35500536, PMID 9369256, PMID 9890307
R01HL144568 (2), 2014 (1), 2019 (1)